Selank Peptide: Research Guide for Canadian Labs

Selank is a synthetic heptapeptide analogue of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg). Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank has been extensively studied in preclinical models for its anxiolytic, nootropic, and immunomodulatory properties — without the sedative or dependency profile associated with classical anxiolytics.

This guide covers Selank's mechanisms, research applications, reconstitution, and dosing for Canadian research laboratories.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment of IgG immunoglobulin. The addition of the Pro-Gly-Pro sequence to the tuftsin backbone dramatically extends its metabolic stability, making it suitable for research applications requiring sustained peptide activity.

Molecular characteristics:

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Molecular weight: 751.9 Da
• CAS number: 129954-34-3
• Stability: Resistant to enzymatic degradation compared to native tuftsin

Selank's research profile spans multiple neurobiological systems:

Preclinical studies suggest Selank modulates GABAergic neurotransmission — the primary inhibitory system in the CNS — without directly binding GABA-A receptors. This is hypothesized to contribute to its anxiolytic effects without the tolerance, dependence, or sedation associated with benzodiazepines.

One of the most studied aspects of Selank is its effect on Brain-Derived Neurotrophic Factor (BDNF). Research in rodent models has demonstrated that Selank administration upregulates BDNF mRNA expression in the hippocampus and frontal cortex. BDNF is critical for neuronal survival, synaptic plasticity, and long-term potentiation — processes central to learning and memory consolidation.

Selank has been shown in preclinical models to modulate serotonergic and dopaminergic neurotransmission. Studies report effects on tryptophan hydroxylase activity and monoamine oxidase (MAO) regulation, which may contribute to its mood-stabilizing research profile.

As a tuftsin analogue, Selank retains immunomodulatory properties. Research has examined its effects on T-lymphocyte activity, interleukin expression (particularly IL-6 and TNF-α), and natural killer (NK) cell function in preclinical models.

Selank has been shown to inhibit enkephalin-degrading enzymes, increasing the half-life of endogenous enkephalins. This may contribute to its anxiolytic and analgesic research properties.

Selank has been investigated across several preclinical research areas:

The most robust preclinical literature on Selank involves anxiety models. Studies using elevated plus maze, open field, and forced swim tests in rodents have consistently demonstrated anxiolytic effects comparable to diazepam — without motor impairment or sedation at equivalent doses.

Rodent studies have examined Selank's effects on spatial memory (Morris water maze), associative learning, and attention. BDNF upregulation is proposed as the primary mechanism underlying observed cognitive improvements.

Research has investigated Selank in models of ischemic brain injury, excitotoxicity, and neuroinflammation. Its anti-inflammatory effects on microglial activation and cytokine production have been studied in vitro and in vivo.

Selank has been studied in models of immune dysregulation, including chronic stress-induced immunosuppression and inflammatory conditions, where it appears to restore cytokine balance.

Selank is supplied as a lyophilized powder and requires reconstitution with bacteriostatic water (BAC water) prior to use.

Suggested reconstitution:

• 5 mg vial + 1 mL BAC water → 5 mg/mL (5,000 mcg/mL)
• 10 mg vial + 2 mL BAC water → 5 mg/mL (5,000 mcg/mL)

For lower concentration working solutions:

• 10 mg vial + 5 mL BAC water → 2 mg/mL (2,000 mcg/mL)

Use our Reconstitution Calculator to calculate volumes for your specific research protocol. See our General Reconstitution Guide for full sterile technique instructions.

The following doses are derived from published preclinical literature and are provided for research reference only.

Note: Selank has also been studied via intranasal administration in preclinical models, which is notable given the peptide's relatively small molecular weight and CNS accessibility via the olfactory route.

Avoid repeated freeze-thaw cycles. Aliquot reconstituted solution if long-term storage is required.

Selank and Semax are often studied together as the two most prominent Russian-developed nootropic peptides. Key distinctions:

Both peptides upregulate BDNF, but via different upstream mechanisms. Some research protocols combine both compounds for complementary nootropic and anxiolytic effects.

Selank 10 mg is currently coming soon at Peptide-Labs. We are completing quality verification and third-party CoA testing before release. Join the waitlist to be notified when Selank becomes available.

Selank is intended solely for in vitro research and preclinical laboratory use. It is not approved for human consumption, veterinary use, or clinical application in Canada. All research must be conducted by qualified professionals in compliance with applicable regulations.